J. L. Goldstein and M. S. Brown, Regulation of the mevalonate pathway, Nature, vol.343, issue.6257, pp.425-455, 1990.
DOI : 10.1038/343425a0

M. F. Demierre, Statins and cancer prevention, Nature Reviews Cancer, vol.62, issue.12, pp.930-972, 2005.
DOI : 10.1038/nrc1751

A. Endo, The discovery and development of HMG-CoA reductase inhibitors, Atherosclerosis Supplements, vol.5, issue.3, pp.1569-82, 1992.
DOI : 10.1016/j.atherosclerosissup.2004.08.026

M. S. Brown, Induction of 3-­?hydroxy-­?3-­?methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-­?236B), a competitive inhibitor of the reductase, J Biol Chem, vol.253, issue.4, pp.1121-1129, 1978.

A. Endo, Compactin (ML-236B) and related compounds as potential cholesterol-lowering agents that inhibit HMG-CoA reductase, Journal of Medicinal Chemistry, vol.28, issue.4, pp.401-406, 1985.
DOI : 10.1021/jm00382a001

V. Quesney-­?huneeus, M. H. Wiley, and M. D. Siperstein, Essential role for mevalonate synthesis in DNA replication, Proceedings of the National Academy of Sciences, vol.76, issue.10, pp.76-5056, 1979.
DOI : 10.1073/pnas.76.10.5056

K. L. Luskey, Amplification of the gene for 3-­?hydroxy-­?3-­?methylglutaryl coenzyme A reductase, but not for the 53-­?kDa protein, in UT-­?1 cells, J Biol Chem, issue.13, pp.258-8462, 1983.

J. F. Hancock, All ras proteins are polyisoprenylated but only some are palmitoylated, Cell, vol.57, issue.7, pp.1167-77, 1989.
DOI : 10.1016/0092-8674(89)90054-8

W. R. Schafer, Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans Evidence for modification of lamin B by a product of mevalonic acid, Science J Biol Chem, vol.245, issue.491613, pp.263-5997, 1988.

L. A. Beck, T. J. Hosick, M. Sinensky-bellosta, S. , R. Paoletti et al., Incorporation of a product of mevalonic acid metabolism into proteins of Chinese hamster ovary cell nuclei Safety of statins: focus on clinical pharmacokinetics and drug interactions Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-­?marketing, J Cell Biol Circulation J Hepatol, vol.10723, issue.1092, pp.1307-1323, 1988.

S. A. Holstein, Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial, Cancer Chemother Pharmacol Lancet, vol.57, issue.29346, pp.360-1623, 2002.

T. E. Strandberg, Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S), The Lancet, vol.364, issue.9436, pp.771-778, 2002.
DOI : 10.1016/S0140-6736(04)16936-5

A. A. Alsheikh-­?ali, Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer, Journal of the American College of Cardiology, vol.50, issue.5, pp.409-427, 2007.
DOI : 10.1016/j.jacc.2007.02.073

C. Baigent, Efficacy and safety of cholesterol-­?lowering treatment: prospective meta-­?analysis of data from 90,056 participants in 14 randomised trials of statins, Lancet, issue.9493, pp.366-1267, 2005.

K. M. Dale, Statins and Cancer Risk, JAMA, vol.295, issue.1, pp.74-80, 2006.
DOI : 10.1001/jama.295.1.74

J. A. Kaye and H. Jick, Statin use and cancer risk in the General Practice Research Database, British Journal of Cancer, vol.90, issue.3, pp.635-642, 2004.
DOI : 10.1038/sj.bjc.6601566

M. R. Graaf, The Risk of Cancer in Users of Statins, Journal of Clinical Oncology, vol.22, issue.12, pp.2388-94, 2004.
DOI : 10.1200/JCO.2004.02.027

J. Haukka, Incidence of cancer and statin usage-Record linkage study, International Journal of Cancer, vol.15, issue.1, pp.279-84, 2010.
DOI : 10.1002/ijc.24536

D. M. Boudreau, O. Yu, and J. Johnson, Statin use and cancer risk: a comprehensive review, Expert Opinion on Drug Safety, vol.26, issue.4, pp.603-624, 2010.
DOI : 10.1161/CIRCULATIONAHA.108.824151

M. W. Medina, Alternative Splicing of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Is Associated With Plasma Low-Density Lipoprotein Cholesterol Response to Simvastatin, Circulation, vol.118, issue.4, pp.355-62, 2008.
DOI : 10.1161/CIRCULATIONAHA.108.773267

J. W. Clendening, Dysregulation of the mevalonate pathway promotes transformation, Proceedings of the National Academy of Sciences, vol.107, issue.34, pp.15051-61, 2010.
DOI : 10.1073/pnas.0910258107

C. Ginestier, Mevalonate Metabolism Regulates Basal Breast Cancer Stem Cells and Is a Potential Therapeutic Target, STEM CELLS, vol.95, issue.7, pp.1327-1364, 2012.
DOI : 10.1002/stem.1122

URL : https://hal.archives-ouvertes.fr/hal-01431941

A. M. Mondul, Association of statin use with pathological tumor characteristics and prostate cancer recurrence after surgery-­?Hydroxy-­?3-­?methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-­?control study, J Urol Arch Intern Med, vol.185, issue.315, pp.1268-73, 2000.

G. J. Fritz, HMG-­?CoA reductase inhibitors (statins) as anticancer drugs (review) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS Air Force/Texas Coronary Atherosclerosis Prevention Study, Int J Oncol JAMA, vol.27, issue.520, pp.279-1615, 1998.

J. N. Poynter, Statins and the Risk of Colorectal Cancer, New England Journal of Medicine, vol.352, issue.21, pp.2184-92, 2005.
DOI : 10.1056/NEJMoa043792

E. J. Jacobs, Cholesterol-Lowering Drugs and Colorectal Cancer Incidence in a Large United States Cohort, JNCI Journal of the National Cancer Institute, vol.98, issue.1, pp.69-72, 2006.
DOI : 10.1093/jnci/djj006

H. B. El-­?serag, Statins Are Associated With a Reduced Risk of Hepatocellular Carcinoma in a Large Cohort of Patients With Diabetes, Gastroenterology, vol.136, issue.5, pp.1601-1609, 2009.
DOI : 10.1053/j.gastro.2009.01.053

M. Shadman, Non-steroidal anti-inflammatory drugs and statins in relation to colorectal cancer risk, World Journal of Gastroenterology, vol.15, issue.19, pp.2336-2345, 2009.
DOI : 10.3748/wjg.15.2336

H. F. Chiu, Statin Use and the Risk of Liver Cancer: A Population-Based Case???Control Study, The American Journal of Gastroenterology, vol.100, issue.5, pp.894-902, 2011.
DOI : 10.1038/ajg.2010.475

K. Hindler, The Role of Statins in Cancer Therapy, The Oncologist, vol.11, issue.3, pp.306-321, 2006.
DOI : 10.1634/theoncologist.11-3-306

Y. G. Shellman, Lovastatin-induced apoptosis in human melanoma cell lines, Melanoma Research, vol.15, issue.2, pp.83-92, 2005.
DOI : 10.1097/00008390-200504000-00001

R. Girgert, Growth inhibition of neuroblastoma cells by lovastatin and l-ascorbic acid is based on different mechanisms, Cancer Letters, vol.137, issue.2, pp.167-72, 1999.
DOI : 10.1016/S0304-3835(98)00355-3

G. Paragh, Different anticancer effects of fluvastatin on primary hepatocellular tumors and metastases in rats, Cancer Letters, vol.222, issue.1, pp.17-22, 2005.
DOI : 10.1016/j.canlet.2004.09.028

J. J. Knox, A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-­?induced apoptosis: therapeutic implications, Eur J Cancer Clin Cancer Res, vol.41, issue.71, pp.158-67, 2001.

V. Khurana, Statins Reduce the Risk of Lung Cancer in Humans, Chest, vol.131, issue.5, pp.1282-1290, 2007.
DOI : 10.1378/chest.06-0931

A. Sassano and L. C. Platanias, Statins in tumor suppression, Cancer Letters, vol.260, issue.1-2, pp.11-20, 2008.
DOI : 10.1016/j.canlet.2007.11.036

A. A. Siddiqui, The long-­?term use of statins is associated with a decreased incidence of adenomatous colon polyps. Digestion, pp.17-22, 2009.

L. Bjorkhem-­?bergman, Lovastatin prevents carcinogenesis in a rat model for liver cancer. Effects of ubiquinone supplementation, Anticancer Res, vol.30, issue.4, pp.1105-1117, 2010.

G. Fritz, C. Henninger, J. Huelsenbeck-nubel, and T. , Potential use of HMG-­?CoA reductase inhibitors (statins) as radioprotective agents Lovastatin protects human endothelial cells from killing by ionizing radiation without impairing induction and repair of DNA double-­?strand breaks, Br Med Bull Clin Cancer Res, vol.973, issue.1, pp.17-26, 2006.

C. Ostrau, Lovastatin attenuates ionizing radiation-induced normal tissue damage in vivo, Radiotherapy and Oncology, vol.92, issue.3, pp.492-501, 2009.
DOI : 10.1016/j.radonc.2009.06.020

J. Wang, Simvastatin Ameliorates Radiation Enteropathy Development After Localized, Fractionated Irradiation by a Protein C-Independent Mechanism, International Journal of Radiation Oncology*Biology*Physics, vol.68, issue.5, pp.68-1483, 2007.
DOI : 10.1016/j.ijrobp.2007.03.036

V. Haydont, Pravastatin Inhibits the Rho/CCN2/Extracellular Matrix Cascade in Human Fibrosis Explants and Improves Radiation-Induced Intestinal Fibrosis in Rats, Clinical Cancer Research, vol.13, issue.18, pp.5331-5371, 2007.
DOI : 10.1158/1078-0432.CCR-07-0625

W. Erl, HMG-CoA reductase inhibitors induce apoptosis in neointima-derived vascular smooth muscle cells, Atherosclerosis, vol.169, issue.2, pp.251-259, 2003.
DOI : 10.1016/S0021-9150(03)00201-6

M. Osmak, Statins and cancer: Current and future prospects, Cancer Letters, vol.324, issue.1, pp.1-12, 2012.
DOI : 10.1016/j.canlet.2012.04.011

S. Kotamraju, C. L. Williams, and B. Kalyanaraman, Statin-Induced Breast Cancer Cell Death: Role of Inducible Nitric Oxide and Arginase-Dependent Pathways, Cancer Research, vol.67, issue.15, pp.67-7386, 2007.
DOI : 10.1158/0008-5472.CAN-07-0993

S. Kato, Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase, J Cell Mol Med, vol.14, issue.5, pp.1180-93, 2010.

K. Gauthaman, Comparative evaluation of the effects of statins on human stem and cancer cells in vitro-­?hydroxy-­?3-­?methylglutaryl-­?coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis, Reprod Biomed Online Gastroenterology, vol.15, issue.32, pp.122-308, 2002.

G. Bocci, Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-­?2 cells Differences in antitumor effects of various statins on human pancreatic cancer, Br J Cancer Int J Cancer, vol.93, issue.36, pp.122-1214, 2005.

O. Mistafa and U. Stenius, Statins inhibit Akt/PKB signaling via P2X7 receptor in pancreatic cancer cells, Biochemical Pharmacology, vol.78, issue.9, pp.1115-1141, 2009.
DOI : 10.1016/j.bcp.2009.06.016

URL : https://hal.archives-ouvertes.fr/hal-00519078

D. G. Menter, Differential Effects of Pravastatin and Simvastatin on the Growth of Tumor Cells from Different Organ Sites, PLoS ONE, vol.69, issue.12, 2011.
DOI : 10.1371/journal.pone.0028813.g006

L. Ravagnan, Peripheral benzodiazepine receptor ligands reverse apoptosis resistance of cancer cells in vitro and in vivo Synergic effect of eicosapentaenoic acid and lovastatin on gene expression of HMGCoA reductase and LDL receptor in cultured HepG2 cells Simvastatin modulates the adhesion and growth of hepatocellular carcinoma cells via decrease of integrin expression and ROCK, Oncogene Cancer Res Lipids Health Dis Int J Oncol, vol.18, issue.6253, pp.2537-2583, 1999.

W. Kim, Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma, Cancer Chemotherapy and Pharmacology, vol.2, issue.Pt 4, pp.497-507, 2009.
DOI : 10.1007/s00280-008-0897-1

Z. Cao, MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-­?CoA reductase Geraniol and simvastatin show a synergistic effect on a human hepatocarcinoma cell line Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-­?regulation of BCL-­?2 gene expression, Cancer Res Cell Biochem Funct Int J Oncol, vol.29, issue.404, pp.71-2286, 2011.

D. Taras, Pravastatin reduces lung metastasis of rat hepatocellular carcinoma via a coordinated decrease of MMP expression and activity, Journal of Hepatology, vol.46, issue.1, pp.69-76, 2007.
DOI : 10.1016/j.jhep.2006.06.015

B. Agarwal, Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells, Clin Cancer Res, issue.58, pp.2223-2232, 1999.

Z. Jin, D. T. Dicker, and W. S. , El-­?Deiry, Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL, Cell Cycle, vol.1, issue.1, pp.82-91, 2002.

W. Wang, E. , and J. Cassidy, Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines, FEBS Letters, vol.57, issue.3, pp.531-415, 2002.
DOI : 10.1016/S0014-5793(02)03575-5

C. Ukomadu and A. Dutta, p21-dependent Inhibition of Colon Cancer Cell Growth by Mevastatin Is Independent of Inhibition of G1 Cyclin-dependent Kinases, Journal of Biological Chemistry, vol.278, issue.44, pp.278-43586, 2003.
DOI : 10.1074/jbc.M307194200

T. Nubel, Lovastatin inhibits Rho-­?regulated expression of E-­?selectin by TNFalpha and attenuates tumor cell adhesion, FASEB J, vol.18, issue.1, pp.140-142, 2004.

M. V. Swamy, Chemoprevention of Familial Adenomatous Polyposis by Low Doses of Atorvastatin and Celecoxib Given Individually and in Combination to APCMin Mice, Cancer Research, vol.66, issue.14, pp.66-7370, 2006.
DOI : 10.1158/0008-5472.CAN-05-4619

E. H. Huang, Atorvastatin induces apoptosis in vitro and slows growth of tumor xenografts but not polyp formation in MIN mice Inhibition of intestinal polyp formation by pitavastatin, a HMG-­?CoA reductase inhibitor, Dig Dis Sci Cancer Prev Res (Phila), vol.55, issue.11 43, pp.445-53, 2010.

H. Xiao, Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway Statins augment the chemosensitivity of colorectal cancer cells inducing epigenetic reprogramming and reducing colorectal cancer cell 'stemness' via the bone morphogenetic protein pathway, Int J Cancer Gastroenterology Gut, vol.122, issue.8711, pp.2115-2139, 2007.

S. J. Cho, Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice, International Journal of Cancer, vol.282, issue.4, pp.951-958, 2008.
DOI : 10.1002/ijc.23593

R. Kaneko, Survivin Down-regulation Plays a Crucial Role in 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitor-induced Apoptosis in Cancer, Journal of Biological Chemistry, vol.282, issue.27, pp.282-19273, 2007.
DOI : 10.1074/jbc.M610350200

J. Lee, Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations NCI60 cancer cell line panel data and RNAi analysis help identify EAF2 as a modulator of simvastatin and lovastatin response in HCT-­?116 cells Prospective analysis of association between use of statins or other lipid-­?lowering agents and colorectal cancer risk, ): p. 674-­?88. 91. Savas, pp.17-27, 2011.

J. Lee, Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study, Cancer Chemotherapy and Pharmacology, vol.123, issue.4, pp.657-63, 2009.
DOI : 10.1007/s00280-008-0913-5

M. Bardou, A. Barkun, and M. Martel, Effect of statin therapy on colorectal cancer, Gut, vol.59, issue.11, pp.1572-85, 2010.
DOI : 10.1136/gut.2009.190900

S. Kawata, Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial, British Journal of Cancer, vol.84, issue.7, pp.886-91, 2001.
DOI : 10.1054/bjoc.2000.1716

B. Vincenzi, Statins may potentiate bisphosphonates anticancer properties: a new pharmacological approach?, Medical Hypotheses, vol.61, issue.1, pp.98-101, 2003.
DOI : 10.1016/S0306-9877(03)00124-5

H. Mo and C. E. Elson, Studies of the isoprenoid-­?mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention, Exp Biol Med (Maywood), issue.7, pp.229-567, 2004.

M. R. Graaf, Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer, Cancer Treatment Reviews, vol.30, issue.7, pp.609-650, 2004.
DOI : 10.1016/j.ctrv.2004.06.010

L. M. Berstein, Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer, Cancer Letters, vol.224, issue.2, pp.203-215, 2005.
DOI : 10.1016/j.canlet.2004.11.011

E. Hawk and J. L. Viner, Statins and Cancer ??? Beyond the ???One Drug, One Disease??? Model, New England Journal of Medicine, vol.352, issue.21, pp.352-2238, 2005.
DOI : 10.1056/NEJMe058074

J. K. Liao and U. Laufs, PLEIOTROPIC EFFECTS OF STATINS, Annual Review of Pharmacology and Toxicology, vol.45, issue.1, pp.89-118, 2005.
DOI : 10.1146/annurev.pharmtox.45.120403.095748

S. Sleijfer, The potential of statins as part of anti-cancer treatment, European Journal of Cancer, vol.41, issue.4, pp.516-538, 2005.
DOI : 10.1016/j.ejca.2004.12.009

A. Thiery-­?vuillemin, Molecularly targeted agents: Their promise as cancer chemopreventive interventions, European Journal of Cancer, vol.41, issue.13, pp.41-2003, 2005.
DOI : 10.1016/j.ejca.2005.06.005

K. Walker and M. F. Olson, Targeting Ras and Rho GTPases as opportunities for cancer therapeutics, Current Opinion in Genetics & Development, vol.15, issue.1, pp.62-70, 2005.
DOI : 10.1016/j.gde.2004.11.001

A. J. Brown, CHOLESTEROL, STATINS AND CANCER, Clinical and Experimental Pharmacology and Physiology, vol.14, issue.3, pp.135-176, 2007.
DOI : 10.1067/mlc.2003.34

T. P. Stossel, The Discovery of Statins, Cell, vol.134, issue.6, pp.903-908, 2008.
DOI : 10.1016/j.cell.2008.09.008

S. Shimoyama, Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers, Cancer Chemotherapy and Pharmacology, vol.295, issue.4, pp.729-768, 2011.
DOI : 10.1007/s00280-011-1583-2

C. Vaklavas, Y. S. Chatzizisis, and A. M. Tsimberidou, Common cardiovascular medications in cancer therapeutics, Pharmacology & Therapeutics, vol.130, issue.2, pp.177-90, 2011.
DOI : 10.1016/j.pharmthera.2011.01.009

S. S. Kanwar, A. Poolla, and A. P. Majumdar, Regulation of colon cancer recurrence and development of therapeutic strategies, World Journal of Gastrointestinal Pathophysiology, vol.3, issue.1, pp.1-9, 2012.
DOI : 10.4291/wjgp.v3.i1.1

M. Thurnher, O. Nussbaumer, and G. Gruenbacher, Novel Aspects of Mevalonate Pathway Inhibitors as Antitumor Agents, Clinical Cancer Research, vol.18, issue.13, pp.18-3524, 2012.
DOI : 10.1158/1078-0432.CCR-12-0489

C. Phospholipase and . Pkc, Protein Kinase C; MAPK: Mitogen Activated Protein Kinase; MEK: MAPK/Extracellular Regulated Kinase; Pi3K: Phosphatidylinositol Tri-­?Phosphate Kinase; mTOR: mammalian Target Of Rapamycin

+. Simvastatin and . Cetuximab, Irinotecan in K-­? ras Mutant Colorectal Cancer Metastatic Colorectal Cancer Drug: cetuximab/irinotecan/simvastatin http://ClinicalTrials.gov/show/NCT01281761 Trial of XELIRI/FOLFIRI + Simvastatin Followed by Simvastatin Maintenance in Metastatic Colorectal Cancer Colorectal Cancer Drug: Simvastatin http

H. Carcinoma|child and B. Drug, Efficacy and Safety Study of Sorafenib Plus Pravastatin to Treat Advanced Hepatocarcinoma Advanced Hepatocarcinoma Drug: Pravastatin http://ClinicalTrials.gov/show/NCT01418729 Gastric cancer Trial of XP (Capecitabine/CDDP) Simvastatin in Advanced Gastric Cancer Patients Gastric Cancer Drug: Simvastatin|Drug: Placebo http://ClinicalTrials.gov/show/NCT01099085 Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Esophageal Cancer|Stomach Cancer Drug: Pravastatin http, ClinicalTrials.gov/show/NCT01038154 Pancreatic cancer Trial of Simvastatin and Gemcitabine in Pancreatic Cancer Patients Pancreatic Cancer Drug: Gemcitabine+simvastatin|Drug: Gemcitabine+Placebo http://ClinicalTrials.gov/show